BGM Group Ltd. (BGM)
割安ファンダメンタル
32
株価
$0.25
時価総額
$100M
パート1 · 企業の価値
概要
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Both are Chinese producers of tetracycline-class antibiotic active ingredients and premixes sold to the same livestock, poultry and feed customers at home and for export.
A non-listed Chinese maker of non-sterile veterinary antibiotic active ingredients and feed additives, selling into the same animal-health raw-material market as BGM's oxytetracycline business.
Makes veterinary antibiotic active ingredients and the finished animal medicines built on them, competing for the large Chinese pig, poultry and aquaculture producers that also buy BGM's products.
A long-established state-backed supplier of veterinary drugs and veterinary active ingredients to Chinese farms, overlapping with BGM on the animal-medicine side of its pharmaceutical segment.
貸借対照表と流動性
売上高
$39M
直近の公表四半期までの12か月 — 1株当たり指標からの推計
純利益
$-25M
直近の公表四半期までの12か月 — 1株当たり指標からの推計
フリーキャッシュフロー
$-5M
自己資本合計
$391M
負債合計
$42M
流動比率
1.24
利払い倍率
-
負債/EBITDA
-
一株当たり利益(EPS)
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$0.49
現在株価
$0.25
安全マージン
+49.0%
適正価値レンジ
$0.47 - $0.52
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-5.1%
P/B レシオ
0.13
P/FCF
-
粗利益率
16.6%
ROIC
-2.5%
収益性レーダー
価値創造(経済的モート)
ROIC
-2.5%
WACC
15.0%
ROIC − WACC
-17.5 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格(4)
- P/B Ratio 0.13
- Debt/Equity ratio
- Current Ratio
- DCF valuation (Undervalued)
不合格(11)
- EPS shows upward trend
- Price CAGR -54.62%
- ROIC -2.5%
- Gross Margin 16.6%
- Operating Margin -33.2%
- Positive Free Cash Flow
- ROE -7.0%
- Revenue Growth 5Y -5.4%
- Share Dilution 1435.7%
- Net Margin Trend -52.6% vs -5.7%
- Piotroski F-Score 3/9
データなし(12)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質:会計処理を調査してください
株式希薄化
新株を発行しており、所有権を希薄化している
機関投資家の保有
この企業について機関投資家の報告はありません。
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Ms. Huandi Zhao | Co-Chief Executive Officer & Director | 40 |
| Ms. Li Hong | Co-Chief Executive Officer | - |
| Ms. Yaxuan Zhai | Chief Financial Officer | 30 |
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for BGM, sourced from Markets Gazette.